<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Infection Immunity and Inflammation</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B2CBCA55-9B41-4A83-897E-ACD96D3458EE"><gtr:id>B2CBCA55-9B41-4A83-897E-ACD96D3458EE</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Brookes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/20FB4AF4-B38E-44EB-BB3F-22B221EAA51B"><gtr:id>20FB4AF4-B38E-44EB-BB3F-22B221EAA51B</gtr:id><gtr:firstName>Dave</gtr:firstName><gtr:surname>Singh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5831A630-7DB2-4F24-A6F3-8E19ABA445F9"><gtr:id>5831A630-7DB2-4F24-A6F3-8E19ABA445F9</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Stockley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6C92C852-396C-4DC4-9339-91AD1A4BA8AD"><gtr:id>6C92C852-396C-4DC4-9339-91AD1A4BA8AD</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Tobin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FE0D06D3-8E96-4D18-B531-03C370F0D6CB"><gtr:id>FE0D06D3-8E96-4D18-B531-03C370F0D6CB</gtr:id><gtr:firstName>Jadwiga</gtr:firstName><gtr:otherNames>Anna</gtr:otherNames><gtr:surname>Wedzicha</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CC41D2A8-AB3F-498B-BC55-CE9ED22CF039"><gtr:id>CC41D2A8-AB3F-498B-BC55-CE9ED22CF039</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Brightling</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/313B7302-C43A-403D-8B55-045248152750"><gtr:id>313B7302-C43A-403D-8B55-045248152750</gtr:id><gtr:firstName>Jorgen</gtr:firstName><gtr:surname>Vestbo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6482DC0F-2D86-4864-8CCC-A851E3F190EB"><gtr:id>6482DC0F-2D86-4864-8CCC-A851E3F190EB</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Burton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001365"><gtr:id>D2FB1016-A841-4378-9A1D-440E652FA040</gtr:id><gtr:title>MRC/ABPI COPD Consortium Work Package 1: COPD Phenotyping</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001365</gtr:grantReference><gtr:abstractText>COPD (which used to be called chronic bronchitis and emphysema) is a common disease which causes considerable difficulty to sufferers. The pharmaceutical industry has been relatively unsuccessful in bringing new treatments to the marketplace for COPD, with many products failing when they are first given to patients. This is largely because not all COPD sufferers are the same and it is likely that drugs will treat certain aspects of the disease and therefore are more likely to benefit some but not all patients. We propose to try to understand what makes people with COPD different from each other and to use these differences to further our understanding of which types of drugs will benefit which types of people. Using this approach we aim to identify markers in blood and sputum that will help us to predict the progression of COPD and response to therapy.</gtr:abstractText><gtr:technicalSummary>Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and healthcare expenditure in the UK (#1B/annum). Worldwide, over 27,000 people died from COPD in 2004 and the WHO forecasts COPD to be the 3rd leading cause of death in the world by 2030. Current therapies are ineffective in preventing the progressive airway remodelling and emphysema, or recurrent exacerbations which are COPD hallmarks. New therapeutic approaches targeting these processes would address a major unmet need. This application will provide the patient-specific data and samples that will underpin the phenotyping effort described here and all the mechanistic studies described in the other work packages of the consortium. This MRC/ABPI COPD consortium will build on existing COPD cohorts and bio-resources from early to established disease and relevant controls. These cohorts and bio-resources include MRC funded, Industry, EU-FP7, NIH, and NIHR-led cohorts. Importantly this application provides the framework for the consortium to evolve to support its changing needs and is sufficiently flexible to allow integration with future initiatives. The available data comprise extensive clinical characterisation, standard physiological measurements, CT-scans, and biological phenotyping from genome to proteome. Additional data are available from some cohorts at exacerbation events complemented with detailed molecular microbiology and virology. In others detailed measures of co-morbidities, activity monitoring, systemic inflammation and skeletal muscle biology has been assessed. We shall harmonise the data between the cohorts and will add follow-up data, and in pre-specified subgroups innovative small airway physiology, imaging and the sampling of tissue and blood to facilitate, target validation and ex vivo modelling and potentially high throughput ?omic? analyses. These data will be used to identify biologically relevant sub-phenotypes required to support the studies outlined in the other work packages, and will be interrogated using bio-statistical modelling to identify novel phenotypes to drive future hypothesis driven mechanistic studies. This connectivity with the other work packages will undergo an iterative process of ?test? and ?validation? groups each further refining the phenotyping effort; informing the mechanistic studies and the sample sizes required for adequate statistical power. Through this integrated joint academic and industry consortium we shall provide the framework necessary to achieve a step-change in our understanding of COPD which we anticipate will lead onto improvements in the treatment of this devastating disease.</gtr:technicalSummary><gtr:fund><gtr:end>2017-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3383164</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>Inflamamtory Therapeutic Capability Clusters (TRPs)</gtr:description><gtr:id>5B1ACCB0-DFC0-48B0-9002-C3B5169F3181</gtr:id><gtr:impact>Collaboration recently commenced</gtr:impact><gtr:outcomeId>VRTL5WxDHsa-1</gtr:outcomeId><gtr:partnerContribution>The Capability Cluster has been awarded to centres in the UK and we are one of the Centres - this includes Imperial, Nottingham, Manchester, KGT, Leicester, Southampton</gtr:partnerContribution><gtr:piContribution>Developed the first protocol for drug development</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>Studies of macrophage phagocytosis in COPD</gtr:description><gtr:id>A0B602E9-29E6-49EB-9765-95D0D131ACA1</gtr:id><gtr:impact>Original Paper published</gtr:impact><gtr:outcomeId>da1fjhR5ABT-1</gtr:outcomeId><gtr:partnerContribution>Expertise in phagocytosis experiments</gtr:partnerContribution><gtr:piContribution>Provision of samples form well phenotyped patients</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>RSV infection and co-morbidity</gtr:description><gtr:id>5803C0F9-4BAD-4743-B556-315F3C1707CE</gtr:id><gtr:impact>In progress
Abstracts to be presented at meetings.
papers in preparation</gtr:impact><gtr:outcomeId>PMpgZqQ7sik-1</gtr:outcomeId><gtr:partnerContribution>Collaborators have provided experience on immunology of RSV</gtr:partnerContribution><gtr:piContribution>Provide COPD patients from cohort that are wekll phenotyped. Studies of viral and bacterial infection and airway and systemic inflammatory markers</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Respiratory Medicine</gtr:department><gtr:description>MRC ABPI COPD Collaboration</gtr:description><gtr:id>948B3B14-ED38-4DBE-A757-67FD4C3B8128</gtr:id><gtr:impact>Contracts now signed and work packages under way</gtr:impact><gtr:outcomeId>fhCXk8nAukh-1</gtr:outcomeId><gtr:partnerContribution>Enabled the MRC ABPI consortium</gtr:partnerContribution><gtr:piContribution>Major part of this collaboration and the London COPD cohort is the main source of patient study and clinical samples</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient cohort meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7F7E2C20-A095-47EE-82DC-E827771D28B4</gtr:id><gtr:impact>Regular meetings of our research cohort, where we discuss studies and also future ones. Review protocols etc.,</gtr:impact><gtr:outcomeId>58c479f26d7543.43703285</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE COPD guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AA7F8B44-234D-4447-9D66-207FFEDC3273</gtr:id><gtr:impact>We have shown the importance of exacerbations in COPD and why they are an important outcome in studies for clinical and economic reasons.</gtr:impact><gtr:outcomeId>4F13A5CF7BD</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B06D29BD-D696-4426-9B8A-1CCF40AC270F</gtr:id><gtr:title>Misspecification of at-risk periods and distributional assumptions in estimating COPD exacerbation rates: The resultant bias in treatment effect estimation.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdfb66698bf12de7c9639a895d0cb7e8"><gtr:id>bdfb66698bf12de7c9639a895d0cb7e8</gtr:id><gtr:otherNames>Law M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>58c477668022e7.68659791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C721CB73-173C-413D-9E88-E81D620DAFAE</gtr:id><gtr:title>Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients.</gtr:title><gtr:parentPublicationTitle>BMC pulmonary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f4691d4afeba46a9833b90572523d93"><gtr:id>2f4691d4afeba46a9833b90572523d93</gtr:id><gtr:otherNames>Lawrence PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2466</gtr:issn><gtr:outcomeId>58c47764f420b5.15773280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C4603BF-BD46-4DE4-9DCD-FF90283E637D</gtr:id><gtr:title>Beta-blockers in COPD: time for reappraisal.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15ac1ceac61efae3b5e2b60458b2522f"><gtr:id>15ac1ceac61efae3b5e2b60458b2522f</gtr:id><gtr:otherNames>Lipworth B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58c47768432903.40428010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7BFC7F8-8FC6-4F50-9D67-61294C23E3E4</gtr:id><gtr:title>Eosinophils as Biomarkers of Chronic Obstructive Pulmonary Disease Exacerbation Risk. Maybe Just for Some?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c4758fc7bae2.42537667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5940ACEB-D263-4663-8408-3FB29AA22B21</gtr:id><gtr:title>How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11b830c588d08eee3ff3f298e8cf1e4c"><gtr:id>11b830c588d08eee3ff3f298e8cf1e4c</gtr:id><gtr:otherNames>Beeh KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47766d0dca5.12658897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4EBC831-70CC-4CA4-A848-58BA897D0BF9</gtr:id><gtr:title>The role of complement activation in COPD exacerbation recovery.</gtr:title><gtr:parentPublicationTitle>ERJ open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/298dc366eae0b645b4c9eae351377e4e"><gtr:id>298dc366eae0b645b4c9eae351377e4e</gtr:id><gtr:otherNames>Westwood JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2312-0541</gtr:issn><gtr:outcomeId>58c477663f82d2.91273842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB64ECD5-82E6-47D1-9BCA-C6E240AD7000</gtr:id><gtr:title>Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn><gtr:outcomeId>58c47765483fc6.12203090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A90899F6-0795-4A04-A560-C0C2E2141681</gtr:id><gtr:title>Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn><gtr:outcomeId>58c47590df6791.54009636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3186B57-8199-4AAD-9FDA-E9DA6026E770</gtr:id><gtr:title>Physical activity and exercise capacity in patients with moderate COPD exacerbations.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8dffe8853ae5656cd9e496c0c8add70"><gtr:id>f8dffe8853ae5656cd9e496c0c8add70</gtr:id><gtr:otherNames>Alahmari AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>58c4759134a6d4.57127566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40E90EB8-0623-49EF-91A6-B5D8A598DBE7</gtr:id><gtr:title>Roflumilast: a review of its use in the treatment of COPD.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn><gtr:outcomeId>58c4759474bca5.89804837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA401D61-1059-4F79-8476-2A69E3C6482F</gtr:id><gtr:title>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fce180d130b001297302c71100206dd6"><gtr:id>fce180d130b001297302c71100206dd6</gtr:id><gtr:otherNames>Vogelmeier CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47765e17239.80169858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E884D2D-9468-4B5E-99EC-4FD1A71A1296</gtr:id><gtr:title>Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/904f884f2cedac3bc8311c15aeb35f7b"><gtr:id>904f884f2cedac3bc8311c15aeb35f7b</gtr:id><gtr:otherNames>Wang Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5a9ea16c9d3132.43982122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C89B5D44-0667-417C-9D5F-34C05C910A4A</gtr:id><gtr:title>Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease &amp;quot;Super Exacerbators&amp;quot;.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47768056125.30590378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4064896E-1263-4E3D-8A3A-83C6DA8AE1FC</gtr:id><gtr:title>Blood eosinophils and inhaled corticosteroid/long-acting ?-2 agonist efficacy in COPD.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/196260af99aec105dadcc0b8ace298d9"><gtr:id>196260af99aec105dadcc0b8ace298d9</gtr:id><gtr:otherNames>Pavord ID</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58c47593ef04a9.86768348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F7F776D-D6B4-443C-BA72-565370E72F98</gtr:id><gtr:title>Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>International journal of chronic obstructive pulmonary disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba4addc1a896e7564698370d1fb5e822"><gtr:id>ba4addc1a896e7564698370d1fb5e822</gtr:id><gtr:otherNames>Barker BL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1176-9106</gtr:issn><gtr:outcomeId>546315eb758db6.86847070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EF553B2-5070-467C-B826-503AAAF29E12</gtr:id><gtr:title>Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT).</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_16417_27_23988767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33926C63-43DF-4846-BC06-B0703353E50E</gtr:id><gtr:title>Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b58adb64320d9f920280ec466c001d1"><gtr:id>5b58adb64320d9f920280ec466c001d1</gtr:id><gtr:otherNames>Roche N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c4776467ffc4.96848265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15B88FAF-7D90-4536-8490-20D8F30E5E70</gtr:id><gtr:title>Chronic Respiratory Symptoms with Normal Spirometry. A Reliable Clinical Entity?</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44262b2dce43af0a517a8d9359049458"><gtr:id>44262b2dce43af0a517a8d9359049458</gtr:id><gtr:otherNames>Rodriguez-Roisin R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47767b978a4.27851056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DB033E8-4554-42C7-85C6-E211C842E2E8</gtr:id><gtr:title>Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8499eff348b9c9cc90ed8296201bbccb"><gtr:id>8499eff348b9c9cc90ed8296201bbccb</gtr:id><gtr:otherNames>Mackay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c477658d4fd4.26021792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD99C32-0FE7-486D-9763-33A2EA82AEDD</gtr:id><gtr:title>Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed08a5f47781b5467e831fe38e0df122"><gtr:id>ed08a5f47781b5467e831fe38e0df122</gtr:id><gtr:otherNames>Wedzicha JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>pm_16417_27_23945277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D6B3D97-CEC2-4060-AEB0-6F92CCE67913</gtr:id><gtr:title>Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.</gtr:title><gtr:parentPublicationTitle>Archivos de bronconeumologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fce180d130b001297302c71100206dd6"><gtr:id>fce180d130b001297302c71100206dd6</gtr:id><gtr:otherNames>Vogelmeier CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-2896</gtr:issn><gtr:outcomeId>58c47764aea073.45250496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C769900-71FA-4DF9-B795-5BA8BE3D8773</gtr:id><gtr:title>Blood and sputum eosinophils in COPD; relationship with bacterial load.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07d54a68b07b2357e4c45ca19ed6669e"><gtr:id>07d54a68b07b2357e4c45ca19ed6669e</gtr:id><gtr:otherNames>Kolsum U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>5a9ea53ff06552.10673061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76D0D6EE-AD23-4B82-9E17-7B4D09F0C0FD</gtr:id><gtr:title>The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ffe59fc47e844902206e70ad18bb1b3"><gtr:id>1ffe59fc47e844902206e70ad18bb1b3</gtr:id><gtr:otherNames>Allinson JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58c47593aa6ec2.07000870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6B34122-43E0-42E1-A9E7-28A9FD82B92B</gtr:id><gtr:title>First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.</gtr:title><gtr:parentPublicationTitle>NPJ primary care respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/343b1902ba6205692a14f688cda3d893"><gtr:id>343b1902ba6205692a14f688cda3d893</gtr:id><gtr:otherNames>Price D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2055-1010</gtr:issn><gtr:outcomeId>58c477671fbab0.73425456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56DBE990-B1F8-4C84-ACA5-B05851976C16</gtr:id><gtr:title>Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6307dbd9b4ae066c0baaf12c18506016"><gtr:id>6307dbd9b4ae066c0baaf12c18506016</gtr:id><gtr:otherNames>Bewley MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c477677823f6.37824265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E6B044F-DEE6-4729-9A7D-A1F105D9E059</gtr:id><gtr:title>Factors associated with change in exacerbation frequency in COPD.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e262baaf0838444302933c5ad7ede29"><gtr:id>8e262baaf0838444302933c5ad7ede29</gtr:id><gtr:otherNames>Donaldson GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>pm_16417_27_23899210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A556683-1968-4B4C-A5FC-1B7D89F76C93</gtr:id><gtr:title>Predicting In-Hospital Treatment Failure (= 7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids.</gtr:title><gtr:parentPublicationTitle>COPD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f73cd47ec8e43d9d3734666f444e5219"><gtr:id>f73cd47ec8e43d9d3734666f444e5219</gtr:id><gtr:otherNames>Crisafulli E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-2563</gtr:issn><gtr:outcomeId>58c47594364bd3.06220809</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001365</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>